Risk assessment of the insecticide Plenum 50 WG by Norwegian Scientific Committee for Food Safety
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opinion of VKM on plant protection products of the Norwegian Scientific  
Committee for Food Safety 
 
Date: 26.06.12  
Doc. no.: 12-206-endelig  
ISBN: 978-82-8259-063-1 
Risk assessment of the insecticide Plenum 50 WG 
with the active substances pymetrozine 
 Norwegian Scientific Committee for Food Safety (VKM) 12-206-endelig 
 
2 
 
Table of Contents 
 
Table of Contents ..................................................................................................................... 1 
Contributors ............................................................................................................................. 3 
Summary ................................................................................................................................... 4 
Background ............................................................................................................................... 5 
Terms of reference ................................................................................................................... 5 
1 Background documentation ........................................................................................ 6 
2 Procedure ...................................................................................................................... 6 
2.1 Health risk assessment ......................................................................................................................... 6 
3 Summary by the Norwegian Food Safety Authority (hazard identification, 
hazard characterization and assessment of exposure) .......................................................... 8 
3.1 Identity and physical/chemical data ..................................................................................................... 8 
3.2 Mammalian toxicology ........................................................................................................................ 9 
3.3 Environmental fate and ecotoxicological effects ............................................................................... 13 
3.4 Dossier quality and completeness ...................................................................................................... 13 
4 Risk characterization ................................................................................................. 14 
4.1 Summary of human toxicity/inherent properties ................................................................................ 14 
4.2 health Risk characterization ............................................................................................................... 18 
5 Conclusion ................................................................................................................... 19 
Attachment .............................................................................................................................. 19 
 
  
 Norwegian Scientific Committee for Food Safety (VKM) 12-206-endelig 
 
3 
 
Contributors 
Persons working for VKM, either as appointed members of the Committee or as ad hoc 
experts, do this by virtue of their scientific expertise, not as representatives for their 
employers. The Civil Services Act instructions on legal competence apply for all work 
prepared by VKM. 
 
Assessed by 
VKMs Panel on plant protection products: 
Line Emilie Sverdrup (Chair), Christine Bjørge, Ole Martin Eklo, Merete Grung, Torsten 
Källqvist, Ingeborg Klingen, Marit Låg, Edgar Rivedal, Erik Ropstad, Steinar Øvrebø.  
 
Scientific coordinator from the secretariat 
Terje Haraldsen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Norwegian Scientific Committee for Food Safety (VKM) 12-206-endelig 
 
4 
 
Summary 
Plenum is a new insecticide containing the new active substance pymetrozine. Plenum is an 
insecticide against different pests in ornamentals, lettuce, cucumber and tomato in greenhouse 
and against pollen beetles in oilseed- and turnip rapes. The risk assessment was finalized at a 
meeting Mai 29, 2012, by VKM’s Scientific Panel on plant protection products (VKM). The 
Panel is in particular asked by the Norwegian Food Safety Authority to look at the following:  
• The human health risk for operators related to the properties of the active substance 
and the product. The Panel is in particular asked to look at the following: 
o The effects seen in studies on dog and if these effects warrant a classification 
for chronic toxicity. 
o The oncogenic effects in liver and lungs 
o The genotoxicity of metabolite CGA 300407. 
o The effects on reproduction and if the effects seen in teratology studies and 
developmental neurotoxicity study warrant a classification for developmental 
toxicity 
o The establishment of NOAELs and reference values (ADI, AOEL and ARfD).  
o The classification and labelling of the active substances and the product. 
 
VKM’s conclusion is as follows:  
The effects reported in the repeated dose toxicity studies with dogs should be considered as 
adverse.  
The increased incidence of liver and lung tumors should be considered as relevant for 
humans. It cannot be excluded that a genotoxic mechanism could be involved in the formation 
of the liver tumors, which would have implications for risk assessment. It should therefore be 
considered to test pymetrozine in more sensitive in vivo genotoxic endpoints in liver.  
 
The effects reported in the teratogenicity studies in rats and rabbits and in the developmental 
neurotoxicity study in rats should be considered for a classification of pymetrozine for 
developmental toxicity.  
Risk calculations with both the German model and the UK POEM show low risk if personal 
protection equipment is used. 
VKM propose: 
• NOAEL of 0.6 mg/kg bw/day for pymetrozine based on the 1-year study in dogs.  
• AOEL of 0.006 mg/kg bw/day for pymetrozine based on the NOAEL value at 0.6 
mg/kg bw/day from the one year study in dogs and an UF of 100. 
• ADI of 0.006 for pymetrozine based on the NOAEL value at 0.6 mg/kg bw/day from 
the one year study in dogs and an UF of 100. 
• ARfD of 0.02 mg/kg bw/day for pymetrozine based on the LOAEL value at 8.1 mg/kg 
bw/day from the developmental neurotoxicity study and an UF of 500 (10 x 
interspecies difference, 10 x intraspecies difference, 3 x due to the use of a LOAEL 
value and 2 x due to the adversity of the neurodevelopmental effects).  
 
VKM supports the classification proposal from Norwegian Food Safety Authority. 
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Background 
VKM performs risk assessments in the context of pesticide registration cf. Regulation on 
Pesticides § 4. The Norwegian Food Safety Authority, National Registration Section, is 
responsible for reviewing and evaluating the documentation submitted by the pesticide 
notifier. The Norwegian Food Safety Authority takes the final regulatory action regarding 
registration or deregistration of pesticides based on VKMs risk assessment, along with a 
comparative assessment of risk and benefits and the availability of alternatives (the principle 
of substitution).  
The Norwegian Food Safety Authority submitted a request on April 20, 2012 for VKM to 
perform a risk assessment on use of the pesticide Plenum containing the active substance 
pymetrozine. The health risk assessments of the product were finalized by VKM in June, 
2012. 
 
Terms of reference 
Plenum 50 WG is a new product containing the new active substance pymetrozine. The 
application is for use against different pests in ornamentals, lettuce, cucumber, and tomato in 
greenhouse, and against pollen beetles in oilseed- and turnip rapes.  
The Norwegian Food Safety Authority would like, in this regard, an assessment of the 
following: 
The human health risk for operators related to the properties of the active substance and the 
product. The Panel is in particular asked to look at the following:  
• The effects seen in studies on dog and if these effects warrant a classification for 
chronic toxicity.  
• The oncogenic effects in liver and lungs.  
• The effects on reproduction and if the effects seen in teratology studies warrant a 
classification for developmental toxicity.  
• The genotoxicity of metabolite CGA 300407. 
• The establishment of NOAELs and reference values (ADI, AOEL and ARfD). 
• The classification and labeling of the active substance and the product. 
 
The Norwegian Food Safety Authority added to the terms of reference in an E-mail 7. May 
2012 (in Norwegian):  
“US EPA har vurdert et forsøk om “ Developmental Neurotoxicity (DNT)” som ikke var 
tilsendt Mattilsynet. Forsøket ble etterspurt og er nå innlevert. Forsøket er ikke standardkrav, 
men utføres når funn i standardforsøk tilsier at stoffet kan ha effekter på utviklingen av 
nervesystemet. 
DNT forsøket med pymetrozin ble ikke vurdert i forbindelse med inkludering av virksomt 
stoff i EU. Mattilsynet viser til US EPAs vurdering av dette forsøkt (se vedlegg, side 8-9). Det 
er bl. a. konkludert med at stoffet gir morfologiske endringer i deler av hjernen hos avkom og 
at dette skjer ved doser som ikke påvirker moren. NOAEL kunne ikke fastsettes. En LOAEL 
på 8 mg/kg/dag ble fastsatt basert på morfologiske endringer i hjernen hos avkommet. 
Faggruppen bes å vurdere om funn i dette forsøket gir en strengere klassifisering enn foreslått 
i vår rapport og om dette forsøket påvirker fastsettelsen av foreslåtte grenseverdier». 
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1 Background documentation 
VKM’s risk assessment is based on the Norwegian Food Safety Authority’s evaluation (2012) 
of the documentation submitted by the applicant. The Norwegian Food Safety Authority 
publishes both their evaluation of Plenum and their final regulatory action on the registration 
of the pesticide product at their homepage (www.Mattilsynet.no) 
 
2 Procedure 
The first three steps of the risk assessment (hazard identification, hazard characterization and 
assessment of exposure) are performed by the Norwegian Food Safety Authority and involve 
an assessment of the documentation submitted by the pesticide notifier. The resulting report 
on hazard identification, hazard characterization and assessment of exposure, from which the 
summary is included in the present document, is then reviewed by VKM. This review may 
result in some amendments in the original documents of both the summary and the full report 
issued by the Norwegian Food Safety Authority (2012). The fourth step (risk characterization) 
is based on the three first steps and is VKM’s conclusions or risk assessment.  
 
2.1 HEALTH RISK ASSESSMENT 
The assessment of health risk of pesticides is based on the adverse effects produced by the 
active substance and product in several experimental test systems including long term animal 
studies. On the basis of this, limits of exposure which represent no health risk are determined. 
The limits take account of the uncertainties of extrapolating data for animal to human. Then 
the limits are compared to the operator exposure and human exposure to possible residues in 
food.  
The UKPoem and the German model estimate of exposure are used to estimate the operator 
exposure. The models are based on a limited number of studies and are not validated. Thus, 
the models may not always be sufficiently representative for Norwegian conditions. The 
limitations of model estimates of exposure are taken into consideration when the calculated 
level of exposure is close to the threshold limit for acceptable operator exposure (Acceptable 
Operator Exposure Level; AOEL). VKM uses the 75 percentile of exposure assessment for 
both UK poem and German model. VKM has to base their assessment on the models 
whenever exposure data for the product is not presented.  
VKM makes use of a higher safety factor when calculating AOEL and ADI in cases where the 
product contains critical active substances with serious adverse inherent properties (toxic to 
reproduction or carcinogenic). 
In order to describe the exceeding of maximum tolerated dose, VKM makes use of a scale. 
The scale is based on the ratio between the estimated exposure based on models or measured 
exposure in field studies and the Acceptable Operator Exposure Level (AOEL). In case the 
estimated exposure significantly exceeds AOEL, use of the products may lead to increased 
risk for health effects.  
 
The following scale is used: 
Very high excess of AOEL more than 500% of the limit   
High excess of AOEL  300 – 500% of the limit  
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Medium excess of AOEL 150-300% of the limit  
Moderate excess of AOEL  100-150% of the limit    
The limit is not exceeded 
VKM may take into consideration critical co-formulants of the product when the degree of 
risk is to be determined. Consequently, if a product contains critical co-formulants it may be 
assessed to represent higher risk than what the inherent properties of active substances imply.   
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3 Summary by the Norwegian Food Safety Authority 
(hazard identification, hazard characterization and 
assessment of exposure) 
Plenum 50 WG is a new product containing the new active substance pymetrozine. 
Pymetrozine was introduced in EU in 1993, and is approved for use till 31.12.2015. The 
formulation of Plenum 50 WG is water soluble granules (WG), containing 500 g/kg of the 
active substance. The application is for use against different pests in ornamentals, lettuce, 
cucumber, and tomato in greenhouse, and against pollen beetles in oilseed- and turnip rapes.  
 
The effect mechanism of Plenum 50 WG differs from all insecticides known so far and also 
covers pests that are resistant against active substances used so far. Plenum 50 WG is an 
insecticide with a specific contact and feed effect against aphids and whiteflies. The insects 
stop sucking/eating immediately after intake of Plenum 50 WG, and the honey dew 
production is also quickly stopped.  
 
Plenum 50 WG will play an important role in reducing risk of resistance development against 
the other insecticides registered for use against biting and sucking insects, particulary against 
neonicotinoids in aphids, and pyriproxifen in whiteflies. Plenum 50 WG is gentle against 
beneficials, except bees and bumblebees. For the turnip- and oil seed rape growers, Plenum 
50 WG may be a useful product for managing pyretroid resistant pollen beetles. 
 
In greenhouses, there is applied to use 120-720 g Plenum 50 WG /ha, depending on culture 
and pest, maximum 3 applications. Against pollen beetles in oilseed and turnip rapes it is 
recommended to use 150 g/ha, maximum 1 application. 
 
Based on the product’s use against pollen beetles in turnip and oil seed rapes the standardized 
area dose is proposed set to 150 g Plenum 50 WG/ha ( 75 g pymetrozine/ha) corresponding 15 
g /daa (7,5 g a.s/daa). 
 
3.1 IDENTITY AND PHYSICAL/CHEMICAL DATA 
Product name  Plenum 50 WG 
 
Active substance pymetrozine 
 
Formulation  wettable granule 
 
Concentration of  
active substance 500 g/kg 
 
IUPAC-name  6-methyl-4-[(E)- (pyridin-3-ylmethylene)amino]-4,5-dihydro-2H 
-[1,2,4]-triazin-3one 
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CAS number  123312-89-0 
 
Structural formula  
 
 
 
Molecular weight 217.2      
 
Water solubility  High    270 g/l (25°C) 
 
Vapour pressure  Low   < 4.2·10-6 Pa (25°C) 
 
Henrys law const.  Low  < 3.0·10-6 Pa·m3/mol 
 
log Pow  Low  -0.19 
 
pKa    4.06 
 
 
3.2 MAMMALIAN TOXICOLOGY 
3.2.1 PYMETROZINE 
3.2.1.1 Toxicokinetics  
Absorption: Orally administered pymetrozine was rapidly and almost completely absorbed 
from the GI into the general circulation. The bioavailability of the oral dose was determined 
to be 0.9 for both sexes, demonstrating a high extent of absorption.  At the high dose level, the 
extent of absorption was greater than at the low dose level. The difference in absorption at the 
high and low dose is assumed to be due to saturation of kinetic processes. In general, females 
of all dose groups had slightly higher total absorption values compared to males. 
 
Distribution: Seven days after administration of radiolabelled pymetrozine, low but detectable 
residues were measured in all tissues and organs. Tissue residues of the pyridine label were 2 
times to 70 times higher compared to the triazine label, and the highest amounts of residues 
were found in heart, skeletal muscle, kidneys, liver and brain.  
 
Metabolism: A large number of metabolites were excreted in urine and faeces. Comparison 
patterns between different groups of rats revealed no qualitative dependence of sex, route of 
administration dose level and pre-treatment. The metabolism of pymetrozine consist of three 
major reactions: Oxidation reactions at the methyl substituent, oxidation reactions at the 
triazine-methylene group, and cleavage reactions between the triazine and the pyridine ring 
systems.  
NN N
N
H
N
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Excretion: Pymetrozine was rapidly and extensively excreted. The principle rout of excretion 
was urine. A higher renal excretion at the high dose level compared to the low dose level was 
seen. The pre-treated animals had slightly higher total excretion values compared to animals 
which had not been pre-treated, this was especially pronounced for males. Considerable 
amounts (12-30%) of pymetrozine were also excreted via biliary excretion. 
 
3.2.1.2 Acute toxicity 
Pymetrozine is of low acute toxicity after oral, dermal and inhalation exposure, and therefore 
no classification is required. Pymetrozine was not found to be neither a skin- or eye irritant 
nor a skin sensitizer. 
 
3.2.1.3 Genotoxicity  
All in vitro and in vivo genotoxicity studies were shown to be negative. 
 
3.2.1.4 Subchronic and chronic toxicity 
Several target organs were identified in the sub-chronic studies on dogs. Myopathy and 
anemia was observed in both the 90-day and 1-year study. Other findings included bile duct 
proliferation, hepatocyte necrosis, skeletal muscle atrophy, lymphocytic infiltration in several 
organs,inflammatory cell infiltration in the liver, increased haemosiderosis in liver and spleen, 
decreased testis weights and increased liver weights.  
 
3.2.1.5 Carcinogenicity  
Increased incidences of liver tumors were seen in chronic studies in mice and rats. There was 
also an increase in lung tumors in female mice.  
The reporting member state (RMS) and the notifier argues that the observed increase in lung 
tumours is not related to the treatment with pymetrozine. The following argumentation is 
given: “There was no increase in the non-neoplastic prestage of lung tumours in mice. The 
incidences of lung tumours in male mice were comparable between all treated groups and the 
concurrent control group. There is no evidence that male mice are less sensitive to 
chemically-induced lung tumours than females. Therefore, the increased incidences of lung 
tumours in females cannot be unequivocally attributed to the application of the test substance” 
The incidences of lung tumours in female mice are, however, above the historical control and 
are therefore believed to be treatment related. 
It is also argued that the liver tumors are a result of a non-genotoxic mechanism as 
pymetrozine was not shown to be genotoxic in any of the performed genotoxicity tests. In 
addition, special studies show that biochemical and morphological changes seen in these 
studies correlate with liver tumors observed in in the chronic studies at same dose levels.  
However, a clear mechanism of action is not demonstrated. The possibility of the liver tumors 
resulting from the genotoxicity of the metabolite CGA 300407 can therefore not be excluded. 
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3.2.1.6 Reproductive toxicology and teratogenesis 
In the rat reproduction study, a decrease in parental and pups body weigh was observed. The 
decrease in the F2 pups body weigh seen from the first week of lactation and onwards 
indicates an effect of the substance through the milk. In the rabbit teratology study an increase 
in post-implantation loss was found. External anomalies and variations were increased. In the 
rat teratology study an increase in external and skeletal malformations and an increase in 
skeletal anomalies and variations were seen. Although these abnormalities were seen at doses 
causing maternal toxicity (reduced food intake and body weigh gain/body weigh loss), it is 
not possible to decide if these effects are secondary to the maternal toxicity. 
 
3.2.1.7 Neurotoxicity 
 
Neurotoxic effects were observed in the acute neurotoxicity study in the rat an included lower 
body temperature, FOB changes and decreased motor activity. In the subchronic neurotoxicity 
excessive head movement and sniffing were seen. The results from these studies show that 
that the nervous system is a target organ for pymetrozine 
 
3.2.1.8 Special studies 
 
Biochemical and morphological changes seen in these studies correlate with mice and rats 
liver tumors observed in in the chronic studies at same dose levels. 
 
3.2.1.9 Human data 
No data reported.  
 
3.2.1.10 Classification and labelling 
The proposed classification is Xn; Carc. Cat. 3, R40 (Possible risks of irreversible effects). 
Rep. Cat. 3, R63 (Possible risk of harm to unborn child). 
 
3.2.1.11 Reference values 
ADI 
The ADI = 0.006 mg/kg/day is proposed to be based on one year dog study with a NOAEL = 
0.6 mg/kg/day and UF of 100. The ADI in EU is based on an overall evaluation of the 90-day 
and one year studies on dog with an overall NOAEL of 3 mg/kg/day giving an ADI of 0.03 
mg/kg/day and an UF of 100.  
AOEL 
The AOEL = 0.006 mg/kg/day is proposed to be based on one year dog study with a NOAEL 
= 0.6 mg/kg/day and UF of 100. The ADI in EU is based on an overall evaluation of the 90-
day and one year studies on dog with an overall NOAEL of 3 mg/kg/day giving an ADI of 
0.03 mg/kg/day and an UF of 100.  
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ARfD 
The ARfD = 0.02 mg/kg/day for pymetrozine based on the LOAEL value at 8.1 mg/kg 
bw/day from the developmental neurotoxicity study and an UF of 500 (10 x interspecies 
difference, 10 x intraspecies difference, 3 x due to the use of a LOAEL value and 2 x due to 
the adversity of the neurodevelopmental effects). 
 
3.2.2 METABOLITES  
 
CGA 300407 is a metabolite identified as a rodent metabolite. It is also occurring in the 
environment and as a residue in plant and animal commodities. This metabolite is shown to be 
mutagenic in vitro and in vivo. The notifier considers the metabolite as an in vivo contact 
mutagen as positive result was seen in the Comet assay in the mouse forestomach, but not in 
the micronucleus test in the mouse bone marrow. The metabolite was however not tested in 
mammalian cells in vitro and not adequately tested in vivo in the liver. The notifier argues that 
the negative comet assay with pymetrozine provides a robust evaluation of the in vivo 
genotoxicity of the metabolite. However, a robust conclusion on the in vivo genotoxicity in 
the liver can only be drawn from further testing of the metabolite. A comet assay in vivo in 
the liver and an analysis of adduct formation or the use of transgenic rodents, should be 
carried out to clarify the in vivo mutagenicity of this metabolite. 
 
3.2.3 CO-FORMULANTS 
Plenum 50 WG does not contain co-formulants occurring above the limit that trigger labelling 
according according to Annex VI of CLP. 
 
 
3.2.4 PLENUM 50 WG 
3.2.4.1 Acute toxicity 
Plenum 50 WG was not harmful by swallowing, skin contact or by inhalation. Plenum 50 WG 
is neither irritating to the eye and skin nor found to be a dermal sensitizer.  
 
3.2.4.2 Classification and labelling    
Plenum is proposed to labeled as Xn; Carc. Cat. 3, R40 (Possible risks of irreversible effects). 
Rep. Cat. 3,R63 (Possible risk of harm to unborn child). 
 
3.2.4.3 Dermal absorption 
A dermal absorption of 6 % for the formulated product and for the diluted product is used in 
the calculation of the exposure. 
 
3.2.4.4 Operator, worker and bystander exposure  
3.2.4.4.1 Operator exposure 
AOEL is exceeded without using the PPE in both models. PPE (Gloves under mixing and 
loading+ A1P2 under mixing +coveralls and sturdy footwear under application) should be 
used for not exceeding the AOEL.  
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3.2.4.4.2 Re-entry and bystander exposure  
Pymetrozine  
AOEL is exceeded for worker harvesting ornamentals and vegetables without using PPE. The 
use of gloves and standard protective garment reduces the exposure bellow the AOEL.  
Metabolite CGA 300407  
The metabolite is found as residue in the plant metabolism studies. The notifier has submitted 
an exposure assessment, considering that this metabolite acts through a threshold process with 
the possibility to set an AOEL. The metabolite is however not sufficiently studied in vivo and 
a possible genotoxic effect cannot be ruled out. It is at the moment not possible to set an 
AOEL for this metabolite. A risk assessment for the metabolite CGA 300407 can not be 
performed as it is not sufficiently studied and a possible in vivo genotoxic effect cannot be 
ruled out. 
 
3.2.5 RESIDUES IN FOOD OR FEED 
Residues are not discussed in this report. 
 
 
3.3 ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL EFFECTS 
Environmental fate and ecotoxicological effects are not discussed in this report. 
 
 
3.4 DOSSIER QUALITY AND COMPLETENESS 
The submitted dossier is in accordance with the data requirements. The studies are conducted 
according to the OECD guidelines and are of acceptable quality. 
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4 Risk characterization 
4.1 SUMMARY OF HUMAN TOXICITY/INHERENT PROPERTIES  
In the terms of reference it was stated that VKM in particular should look at the following: 
The Norwegian Food Safety Authority would like, in this regard, an assessment of the 
following: 
The human health risk for operators related to the properties of the active substance and the 
product. The Panel is in particular asked to look at the following:  
• The effects seen in studies on dog and if these effects warrant a classification for 
chronic toxicity.  
• The oncogenic effects in liver and lungs.  
• The genotoxicity of metabolite CGA 300407. 
• The effects on reproduction and if the effects seen in teratology studies and in   
developmental Neurotoxicity (DNT) study warrant a classification for developmental 
toxicity.  
• The establishment of NOAELs and reference values (ADI, AOEL and ARfD). 
• The classification and labeling of the active substance and the product. 
 
 
VKM discussed these points in-depth: 
 
4.1.1 THE EFFECTS SEEN IN STUDIES ON DOG  
From the summary (chapter 3.2.1.4) and the Norwegian Food Safety Authority’s evaluation 
(2012):  
“Several target organs were identified in the sub-chronic studies on dogs. Myopathy and 
anemia was observed in both the 90-day and 1-year study. Other findings included bile duct 
proliferation, hepatocyte necrosis, skeletal muscle atrophy, lymphocytic infiltration in several 
organs, inflammatory cell infiltration in the liver, increased haemosiderosis in liver and 
spleen, decreased testis weights and increased liver weights”.  
 
4.1.1.1 The opinion of VKM 
Effects were reported in a 90 day and one year study in dogs. These effects included; severe 
anemia, adverse changes in haematology, hepatocellular necrosis, atrophy of the thymus, 
increased cholesterol levels, myopathy, and increased splenic and hepatic hemosiderosis. In 
males atrophy of testis and reduced spermatogenesis was reported as well.  Some of these 
effects were present after the recovery period. Effects were reported from 14 mg/kg bw/day in 
the 90 days study and from 5 mg/kg bw/day in the one year study. The effects reported should 
be considered as adverse. The NOAEL from the one year study was 0.6 mg/kg bw/day and is 
used for deriving ADI and AOEL.  
 
4.1.2 THE ONCOGENIC EFFECTS IN LIVER AND LUNGS  
From the summary (chapter 3.2.1.5) and the Norwegian Food Safety Authority’s evaluation 
(2012):  
“Increased incidences of liver tumors were seen in chronic studies in mice and rats. There 
was also an increase in lung tumors in female mice.  
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The reporting member state (RMS) and the notifier argues that the observed increase in lung 
tumours is not related to the treatment with pymetrozine. The following argumentation is 
given: “There was no increase in the non-neoplastic prestage of lung tumours in mice. The 
incidences of lung tumours in male mice were comparable between all treated groups and the 
concurrent control group. There is no evidence that male mice are less sensitive to 
chemically-induced lung tumours than females. Therefore, the increased incidences of lung 
tumours in females cannot be unequivocally attributed to the application of the test 
substance” 
The incidences of lung tumours in female mice are, however, above the historical control and 
are therefore believed to be treatment related. 
It is also argued that the liver tumors are a result of a non-genotoxic mechanism as 
pymetrozine was not shown to be genotoxic in any of the performed genotoxicity tests. In 
addition, special studies show that biochemical and morphological changes seen in these 
studies correlate with liver tumors observed in in the chronic studies at same dose levels.  
However, a clear mechanism of action is not demonstrated. The possibility of the liver tumors 
resulting from the genotoxicity of the metabolite CGA 300407 can therefore not be excluded”. 
 
 
 
4.1.3 THE GENOTOXICITY OF METABOLITE CGA 300407.  
From the summary (chapter 3.2.2): 
“CGA 300407 is a metabolite identified as a rodent metabolite. It is also occurring in the 
environment and as a residue in plant and animal commodities. This metabolite is shown to 
be mutagenic in vitro and in vivo. The notifier considers the metabolite as an in vivo contact 
mutagen as positive result was seen in the Comet assay in the mouse forestomach, but not in 
the micronucleus test in the mouse bone marrow. The metabolite was however not tested in 
mammalian cells in vitro and not adequately tested in vivo in the liver. The notifier argues 
that the negative comet assay with pymetrozine provides a robust evaluation of the in vivo 
genotoxicity of the metabolite. However, a robust conclusion on the in vivo genotoxicity in the 
liver can only be drawn from further testing of the metabolite. A comet assay in vivo in the 
liver and an analysis of adduct formation or the use of transgenic rodents, should be carried 
out to clarify the in vivo mutagenicity of this metabolite”. 
 
4.1.3.1 The opinion of VKM  
Exposure to pymetrozine resulted in increased incidences of liver tumours in female rats that 
were above the historical control data (HCD) and in male and female mice. An increase in 
lung adenoma plus carcinoma was reported in female mice that were above the HCD.  
 
Several arguments are presented to suggest that the tumors observed are unrelated to the 
exposure to pymetrozine. VKM has however not been convinced by these arguments, and 
have the opinion that it cannot be excluded that the observed tumors are relevant to human 
exposure.   
 
A central question is whether the tumors result from a non-genotoxic mechanism, considering 
that pymetrozine has not been shown to be genotoxic.  A complicating finding is however that 
of a genotoxic metabolite, CGA 300407.  
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The metabolite CGA 300407 gave positive response in vitro for chromosomal aberrations in 
CHO cells and human lymphocytes, and in vivo in a Comet assay in mouse forestomach. It is 
argued that the metabolite could be considered as a locally acting genotoxin in the 
forestomach, and thus not be involved in the formation of the liver tumors. However, the 
metabolite may also be formed by direct transformation of the mother substance in the liver.  
 
It is the opinion of VKM that it cannot be excluded that a genotoxic mechanism could be 
involved in the formation of the liver tumors, which would have implications for risk 
assessment. It should therefore be considered to test pymetrozine in more sensitive in vivo 
genotoxic endpoints in liver.  
 
 
4.1.4 THE EFFECTS ON REPRODUCTION  
From the summary (chapter 3.2.1.6): 
“In the rat reproduction study, a decrease in parental and pups body weigh was observed. 
The decrease in the F2 pups body weigh seen from the first week of lactation and onwards 
indicates an effect of the substance through the milk. In the rabbit teratology study an 
increase in post-implantation loss was found. External anomalies and variations were 
increased. In the rat teratology study an increase in external and skeletal malformations and 
an increase in skeletal anomalies and variations were seen. Although these abnormalities 
were seen at doses causing maternal toxicity (reduced food intake and body weight gain/body 
weight loss), it is not possible to decide if these effects are secondary to the maternal 
toxicity”. 
 
4.1.4.1 The opinion of VKM 
No effects on reproductive parameters were reported in a 2-generation study in rats. A dose-
depended increase in early resorptions was reported in a teratology study in rabbits. In 
repeated dose toxicity studies in rats reduced spermatogenesis and reduced spermatozoa in 
epididymis was reported. In dogs reduced testes weight, minimal atrophy of the testis as well 
as atrophy of prostatic glandular tissue was reported as well. These effects could be 
considered relevant for humans. 
 
In a teratology study in rats increase in external abnormalities and skeletal malformations that 
was above the historical control data was reported. Maternal effects included a significant 
reduced body weight. In a teratogenicity study in rabbits a dose-depended increase in post-
implantation loss was reported and one dam aborted and 3 dams resorbed litters completely. 
External anomalies were significantly increased and were above the historical control data. 
Maternal toxicity was evident as significantly reduced body weight gain. It cannot be 
excluded that the abnormalities reported in the pups and the increase in post-implantation loss 
could be secondary to maternal toxicity. 
   
In a rat developmental neurotoxicity study changes in brain morphometry were reported in 
pups including increased thickness of the corpus callosum and inner granular and molecular 
layers of the pre-pyramidal fissure in the cerebellum in males at pnd 63 and dorsal cortex in 
females at pnd 12. All dams in the high dose group were sacrificed prior to scheduled 
termination due to clinical signs of toxicity and complete litter losses. Changes in brain 
morphometry were reported in the absence of maternal toxicity and are considered as an 
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adverse effect in pups.  The LOAEL from this study was 8.1 mg/kg bw/day and is used for 
deriving ARfD.   
 
In the 2-generation study in rats a decrease in pup weight   was reported from the second 
week of lactation in F1 and from the first week of lactation in F2. The data gives no 
information if the decrease in pup body weight was related to exposure to Pymetrozine from 
milk, or is related to decreased milk production by the dams. Since pups starts to eat around 
this time it is also difficult to conclude if the decrease in pup weight is related to direct 
exposure to Pymetrozien from food.  
 
VKM concluded that the effects reported in the teratogenicity studies in rats and rabbits and 
in the developmental neurotoxicity study in rats should be considered for a classification of 
pymetrozine for developmental toxicity.  
 
4.1.5 ESTABLISHMENT OF REFERENCE VALUES:  
NOAEL 
EU has proposed a NOAEL of 3 mg/kg bw/day for calculation of ADI and AOEL. The 
Norwegian Food Safety Authority proposes a NOAEL of 0.6 mg/kg bw/d from the study with 
one-year diet study with dog.  
VKM support an NOAEL of 0.6 mg/kg bw/day for pymetrozine based on the 1-year study in 
dogs.  
 
ADI  
An ADI of 0.006 mg/kg bw/day is proposed to be based on one year dog study with a 
NOAEL = 0.6 and UF=100.  
The ADI in EU is based on an overall evaluation of the 90-day and one year studies on dog 
with an overall NOAEL of 3 mg/kg/day giving an ADI of 0.03 mg/kg/day and an UF of 100.  
VKM support an ADI of 0.006 mg/kg bw/day for pymetrozine based on the NOAEL value at 
0.6 mg/kg bw/day from the one year study in dogs and an UF of 100.  
 
AOEL  
0.006 mg/kg bw/day is proposed to be based on one year dog study with a NOAEL = 0,6 and 
UF=100.  
The AOEL in EU is based on an overall evaluation of the 90-day and one year studies on dog 
with an overall NOAEL of 3 mg/kg/day giving an ADI of 0.03 mg/kg/day and an UF of 100.  
 
The metabolite CGA 300407  
The metabolite is found as residue in the plant metabolism studies. The notifier has submitted 
an exposure assessment, considering that this metabolite acts through a threshold process with 
the possibility to set an AOEL. The metabolite is however not sufficiently studied in vivo and 
a possible genotoxic effect cannot be ruled out. It is at the moment not possible to set an 
AOEL for this metabolite. A risk assessment for the metabolite CGA 300407 cannot be 
performed as it is not sufficiently studied and a possible in vivo genotoxic effect cannot be 
ruled out.  
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VKM support an AOEL of 0.006 mg/kg bw/day for pymetrozine based on the NOAEL value 
at 0.6 mg/kg bw/day from the one year study in dogs and an UF of 100. 
 
ARfD  
The ARfD = 0.1 mg/kg is proposed to be based on rat teratology study with a NOAEL = 10 
mg/kg/day and UF = 100. This is the same ARfD as in EU. 
VKM proposes an ARfD of 0.02 mg/kg bw/day for pymetrozine based on the LOAEL value 
at 8.1 mg/kg bw/day from the developmental neurotoxicity study and an UF of 500 (10 x 
interspecies difference, 10 x intraspecies difference, 3 x due to the use of a LOAEL value and 
2 x due to the adversity of the neurodevelopmental effects).  
 
 
4.1.6 THE CLASSIFICATION AND LABELLING OF THE ACTIVE SUBSTANCE AND THE 
PRODUCT. 
Plenum is proposed to be labeled as Xn; Carc. Cat. 3, R40 (Possible risks of irreversible 
effects). Rep. Cat. 3, R63 (Possible risk of harm to unborn child). 
VKM supports the classification proposal from Norwegian Food Safety Authority. 
 
4.2 HEALTH RISK CHARACTERIZATION  
Health risk due to human exposure 
VKM has based their risk characterization for operators on the summary from Norwegian 
Food Safety Authority presented in section 5.3 and on the exposure- and dose-response 
assessments presented in section 5.2.1 by applying the scale of exceed of AOEL. 
Operator, worker and bystander exposure 
Operator exposure 
AOEL is exceeded without using the PPE in both models. PPE (Gloves under mixing and 
loading+ A1P2 under mixing +coveralls and sturdy footwear under application) should be 
used for not exceeding the AOEL.  
Re-entry and bystander exposure  
AOEL is exceeded for worker harvesting ornamentals and vegetables without using PPE. The 
use of gloves and standard protective garment reduces the exposure bellow the AOEL.  
Health risk due to residues in products for consumption  
Not included in the terms of reference. 
 
4.2.1 QUALITY OF THE SUBMITTED DOCUMENTATION 
VKM is of the opinion that the documentation submitted to VKM is adequate as a basis for an 
evaluation of the active substance, the metabolites, and for the technical material.  
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5 Conclusion 
The effects reported in the repeated dose toxicity studies with dogs should be considered as 
adverse.  
The increased incidence of liver and lung tumours should be considered as relevant for 
humans. It is the opinion of VKM that it cannot be excluded that a genotoxic mechanism 
could be involved in the formation of the liver tumors, which would have implications for risk 
assessment. It should therefore be considered to test pymetrozine for more sensitive in vivo 
genotoxic endpoints in liver.  
 
VKM concluded that the effects reported in the teratogenicity studies in rats and rabbits and 
in the developmental neurotoxicity study in rats should be considered for a classification of 
pymetrozine for developmental toxicity.  
VKM proposes: 
• NOAEL of 0.6 mg/kg bw/day for pymetrozine based on the 1-year study in dogs.  
• AOEL of 0.006 mg/kg bw/day for pymetrozine based on the NOAEL value at 0.6 
mg/kg bw/day from the one year study in dogs and an UF of 100. 
• ADI of 0.006 for pymetrozine based on the NOAEL value at 0.6 mg/kg bw/day from 
the one year study in dogs and an UF of 100. 
• ARfD of 0.02 mg/kg bw/day for pymetrozine based on the LOAEL value at 8.1 mg/kg 
bw/day from the developmental neurotoxicity study and an UF of 500 (10 x 
interspecies difference, 10 x intraspecies difference, 3 x due to the use of a LOAEL 
value and 2 x due to the adversity of the neurodevelopmental effects).  
 
VKM supports the classification proposal from Norwegian Food Safety Authority. 
Risk calculations with both the German model and the UK POEM show low risk if personal 
protection equipment is used. 
 
 
 
 
 
 
 
 
Attachment 
Attached is The Norwegian Food Safety Authority’s evaluation of the documentation 
submitted by the applicant, folowing application  for registration of the insecticide Plenum 
(www.Mattilsynet.no) 
 
 
